Article
C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.
Immunopharmacology and immunotoxicology - 1 Jan 2015
Tobío Araceli, Alfonso Amparo, Botana Luis M
Abstract excerpt
PURPOSE: The second generation of tyrosine kinase inhibitors is a group of compounds that inhibit c-kit receptor activity and therefore widely used in the treatment of mastocytosis. In this research, the relationship between the mechanism of action of tyrosine kinase inhibitors and protein kinase C is investigated in HMC-1(560) or HMC-1(560,816) cell lines. RESULTS: From all the tyrosine kinase inhibitors tested,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
